Xu Ming, Xu Song, Jiang Bowen, Man Zhongran
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui.
Department of Hepatobiliary Surgery, Shangyu People's Hospital of Shaoxing City, Shaoxing, People's Republic of China.
Ann Med Surg (Lond). 2024 Jan 4;86(3):1396-1400. doi: 10.1097/MS9.0000000000001665. eCollection 2024 Mar.
Patients with gallbladder cancer (GBC) generally receive gemcitabine as the standard treatment; however, its efficacy is often limited owing to the development of resistance.
To identify the mechanisms underlying gemcitabine resistance in GBC, a gemcitabine-resistant GBC cell line (NOZ GemR) was established by exposing the parental NOZ cell line to increasing concentrations of gemcitabine. Morphological changes, growth rates, and migratory and invasive capabilities were evaluated. Protein expression was detected using western blotting.
The results demonstrated that the IC of NOZ and NOZ GemR was 0.011 and 4.464 μM, respectively, and that the resistance index ratio was 405.8. In comparison, NOZ GemR cells grew slower and had significantly lower migration and invasion abilities than NOZ cells. There were altered levels of epithelial-mesenchymal transformation markers in NOZ GemR cells, as well as increased levels of the Akt/mTOR pathway protein.
The NOZ GemR cell line could be used as an effective in vitro model to improve our understanding of gemcitabine resistance in GBC.
胆囊癌（GBC）患者通常接受吉西他滨作为标准治疗；然而，由于耐药性的产生，其疗效往往有限。
为了确定GBC中吉西他滨耐药的潜在机制，通过将亲本NOZ细胞系暴露于浓度递增的吉西他滨中，建立了吉西他滨耐药的GBC细胞系（NOZ GemR）。评估了形态变化、生长速率以及迁移和侵袭能力。使用蛋白质印迹法检测蛋白质表达。
结果表明，NOZ和NOZ GemR的半数抑制浓度（IC）分别为0.011和4.464 μM，耐药指数比为405.8。相比之下，NOZ GemR细胞生长较慢，迁移和侵袭能力明显低于NOZ细胞。NOZ GemR细胞中上皮-间质转化标志物水平发生改变，Akt/mTOR通路蛋白水平也升高。
NOZ GemR细胞系可作为一种有效的体外模型，以增进我们对GBC中吉西他滨耐药性的理解。
